To date, PD-1/PD-L1 combination therapy has demonstrated robust clinical efficacy in managing various cancers, including non-small cell lung cancer, colorectal cancer, gastric cancer, breast cancer, and liver cancer, where it can work synergistically with radiotherapy, chemotherapy, and targeted treatments to combat tumours. Here, CD274 is linked to non-small cell lung carcinoma.